查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1566840

阿米巴细胞裂解物市场：按类型、按应用：2024-2033 年全球机会分析与产业预测

Amebocyte Lysate Market By Type (Limulus Amebocyte Lysate, Tachypleus Amebocyte Lysate) , By Application (Drug Testing, Clinical Diagnosis, Other) : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3个工作天内

价格
简介目录

阿米巴细胞裂解液市场

2023年阿米巴细胞裂解物市值为6亿美元，预计2024年至2033年复合年增长率为11.8%，2033年达到19亿美元。

变形细胞裂解物从鲎血细胞或变形细胞中获得，以其在细菌内毒素存在下独特的凝血特性而闻名。阿米巴裂解物是生物医学研究和製药领域的重要组成部分，特别是用于细菌内毒素的检测。由于其出色的灵敏度，阿米巴细胞裂解物可用于环境监测，特别是用于水和其他环境样品的细菌污染的品质评估。

药物测试领域是阿米巴细胞裂解物市场的关键驱动力。变形细胞裂解物和边缘变形细胞裂解物 (LAL) 测试用于药物开发的药物测试的多个阶段，包括原料测试、进程内测试和最终产品测试。最近，重组 DNA 技术已趋向于利用变形虫细胞裂解物的特性进行各种应用。该技术开发了阿米巴细胞裂解物遗传成分的副本，并已证明其具有可扩展性、一致性和减少对鲎种群的依赖等优势。

然而，遵守每个国家颁布的药典法规对于市场相关人员来说是一项复杂且成本高昂的挑战，阻碍了市场成长。此外，有关在测试中使用动物以及用于生产阿米巴细胞裂解物的自然资源的永续性的伦理考虑正在阻碍市场开拓。为了解决这些问题，研究发现组织 AmeboGenesis(TM) 推出了一种可持续的变形虫细胞生产方法。这是一种创新方法，采用可持续的方法，收穫鲎腿肌肉，进行培养，并使用全能干细胞分化为变形虫细胞。该过程极大地控制了变形虫细胞的产生，并确保了稳定的鲎试剂浓度和产量。这种方法每年阻止约 80 万隻鲎的捕获和放血，捕获后的存活率非常低。

板块回顾

阿米巴细胞裂解物市场分为类型、应用和区域。依类型分为边缘阿米巴细胞裂解物和胸腺阿米巴细胞裂解物。依应用范围分为药物检测、临床诊断等。从区域来看，分析涵盖北美、欧洲、亚太地区和拉丁美洲/中东/非洲。

主要发现

按类型划分，边缘变形细胞裂解物细分市场是 2023 年的主要股东。

从应用来看，药物检测领域在 2023 年占据了主要份额。

预计到 2033 年，亚太地区阿米巴细胞裂解物市场将快速成长。

该报告可以定制（需要单独的费用和时间表）。

  • 监管指引
  • 根据客户兴趣加入公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 扩大公司简介列表
  • 主要参与企业的详细资料（Excel格式，包括位置、联络资讯、供应商/供应商网路等）

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 关键投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章 变形细胞裂解物市场：依类型

  • 市场概况
  • 边缘阿米巴细胞裂解物
  • 胸腺变形细胞裂解物

第五章 变形细胞裂解物市场：依应用分类

  • 市场概况
  • 药物测试
  • 临床诊断
  • 其他的

第六章阿米巴细胞裂解物市场：按地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国阿米巴细胞裂解液市场
    • 加拿大阿米巴细胞裂解液市场
    • 墨西哥阿米巴细胞裂解液市场
  • 欧洲
    • 主要市场趋势和机会
    • 德国阿米巴细胞裂解液市场
    • 法国阿米巴细胞裂解液市场
    • 英国阿米巴细胞裂解液市场
    • 义大利阿米巴细胞裂解液市场
    • 西班牙阿米巴细胞裂解液市场
    • 其他欧洲阿米巴细胞裂解物市场
  • 亚太地区
    • 主要市场趋势和机会
    • 日本阿米巴细胞裂解液市场
    • 中国阿米巴细胞裂解液市场
    • 澳洲阿米巴细胞裂解液市场
    • 印度阿米巴细胞裂解液市场
    • 韩国阿米巴细胞裂解液市场
    • 其他亚太变形细胞裂解物市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西阿米巴细胞裂解液市场
    • 沙乌地阿拉伯变形细胞裂解物市场
    • 南非阿米巴细胞裂解液市场
    • 其他拉丁美洲/中东/非洲阿米巴细胞裂解物市场

第七章 竞争状况

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 有竞争力的仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第八章 公司简介

  • Lonza Group AG
  • Charles River Laboratories
  • Associates of Cape Cod Inc
  • Xiamen Bioendo Technology
  • Zhanjiang A&C Biological
  • Genscript Technology Corporation
  • Nelson Laboratories, LLC
  • Thermo Fisher Scientific, Inc.
  • Merck And Co., Inc.
  • Microcoat Biotechnologie GmbH
简介目录
Product Code: A65445

Amebocyte Lysate Market

The amebocyte lysate market was valued at $0.6 billion in 2023 and is projected to reach $1.9 billion by 2033, growing at a CAGR of 11.8% from 2024 to 2033.

Amebocyte lysate, derived from the blood cells or amebocytes of horseshoe crabs, is well-known for its unique property of clotting in the presence of bacterial endotoxins. It is a crucial component in the field of biomedical research & pharmaceuticals and is particularly utilized for the detection of bacterial endotoxins. Due to its exceptional sensitivity, amebocyte lysate is used in environmental monitoring, particularly for the assessment of quality of water and other environmental samples for bacterial contamination.

The field of drug testing is a significant driver of the amebocyte lysate market. Several stages of drug testing such as raw material testing, in-process testing, and final product testing make use of amebocyte lysate and limulus amebocyte lysate (LAL) test for pharmaceutical development. In recent times, recombinant DNA technology is trending for the utilization of properties of amebocyte lysate in different applications. Ther technology develops copies of the genetic components of amebocyte lysate and offers benefits such as scalability, consistency, & reduced reliance on horseshoe crab populations.

However, compliance with the pharmacopeial regulations established in different countries is a complex and expensive challenge for the market players which prevents the growth of the market. In addition, the ethical considerations regarding the usage of animals in testing and the sustainability of natural resources used in amebocyte lysate production hinder market development. To combat such issues, AmeboGenesis(TM), a research and discovery organization, introduced a sustainable way of production of amebocytes. This is an innovative method which utilizes a sustainable approach involving the reaping of leg muscles of a horseshoe crab, culturing, and differentiating them into amebocytes by the use of totipotent stem cells. This process ensures a significant control over amebocyte production, along with consistent LAL concentration & production. This approach prevents the annual harvest and bleeding of approximately 800,000 horseshoe crabs, with a notably low survival rate post-harvesting.

Segment Review

The amebocyte lysate market is segmented into type, application, and region. By type, the market is bifurcated into limulus amebocyte lysate and tachypleus amebocyte lysate. On the basis of application, it is divided into drug testing, clinical diagnosis, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the limulus amebocyte lysate segment was the major shareholder in 2023.

Depending on application, the drug testing segment garnered a major share in 2023.

The amebocyte lysate market is expected to experience rapid growth In Asia Pacific by 2033.

Competition Analysis

The major players operating in the global amebocyte lysate market include Lonza Group AG, Charles River Laboratories, Associates Of Cape Cod, Xiamen Bioendo Technology, Zhanjiang A&c Biological, GenScript, Nelson Laboratories, LLC, Thermo Fisher Scientific, Inc., Merck & Co, and Microcoat Biotechnologie GmbH. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

  • Limulus Amebocyte Lysate
  • Tachypleus Amebocyte Lysate

By Application

  • Drug Testing
  • Clinical Diagnosis
  • Other

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Lonza Group AG
    • Charles River Laboratories
    • Associates of Cape Cod Inc
    • Xiamen Bioendo Technology
    • Zhanjiang A&C Biological
    • Genscript Technology Corporation
    • Nelson Laboratories, LLC
    • Thermo Fisher Scientific, Inc.
    • Merck & Co., Inc.
    • Microcoat Biotechnologie GmbH

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: AMEBOCYTE LYSATE MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. Limulus Amebocyte Lysate
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Tachypleus Amebocyte Lysate
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country

CHAPTER 5: AMEBOCYTE LYSATE MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Drug Testing
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Clinical Diagnosis
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Other
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: AMEBOCYTE LYSATE MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Type
    • 6.2.3. Market Size and Forecast, By Application
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Amebocyte Lysate Market
      • 6.2.5.1. Market Size and Forecast, By Type
      • 6.2.5.2. Market Size and Forecast, By Application
    • 6.2.6. Canada Amebocyte Lysate Market
      • 6.2.6.1. Market Size and Forecast, By Type
      • 6.2.6.2. Market Size and Forecast, By Application
    • 6.2.7. Mexico Amebocyte Lysate Market
      • 6.2.7.1. Market Size and Forecast, By Type
      • 6.2.7.2. Market Size and Forecast, By Application
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Type
    • 6.3.3. Market Size and Forecast, By Application
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. Germany Amebocyte Lysate Market
      • 6.3.5.1. Market Size and Forecast, By Type
      • 6.3.5.2. Market Size and Forecast, By Application
    • 6.3.6. France Amebocyte Lysate Market
      • 6.3.6.1. Market Size and Forecast, By Type
      • 6.3.6.2. Market Size and Forecast, By Application
    • 6.3.7. UK Amebocyte Lysate Market
      • 6.3.7.1. Market Size and Forecast, By Type
      • 6.3.7.2. Market Size and Forecast, By Application
    • 6.3.8. Italy Amebocyte Lysate Market
      • 6.3.8.1. Market Size and Forecast, By Type
      • 6.3.8.2. Market Size and Forecast, By Application
    • 6.3.9. Spain Amebocyte Lysate Market
      • 6.3.9.1. Market Size and Forecast, By Type
      • 6.3.9.2. Market Size and Forecast, By Application
    • 6.3.10. Rest of Europe Amebocyte Lysate Market
      • 6.3.10.1. Market Size and Forecast, By Type
      • 6.3.10.2. Market Size and Forecast, By Application
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Type
    • 6.4.3. Market Size and Forecast, By Application
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. Japan Amebocyte Lysate Market
      • 6.4.5.1. Market Size and Forecast, By Type
      • 6.4.5.2. Market Size and Forecast, By Application
    • 6.4.6. China Amebocyte Lysate Market
      • 6.4.6.1. Market Size and Forecast, By Type
      • 6.4.6.2. Market Size and Forecast, By Application
    • 6.4.7. Australia Amebocyte Lysate Market
      • 6.4.7.1. Market Size and Forecast, By Type
      • 6.4.7.2. Market Size and Forecast, By Application
    • 6.4.8. India Amebocyte Lysate Market
      • 6.4.8.1. Market Size and Forecast, By Type
      • 6.4.8.2. Market Size and Forecast, By Application
    • 6.4.9. South Korea Amebocyte Lysate Market
      • 6.4.9.1. Market Size and Forecast, By Type
      • 6.4.9.2. Market Size and Forecast, By Application
    • 6.4.10. Rest of Asia-Pacific Amebocyte Lysate Market
      • 6.4.10.1. Market Size and Forecast, By Type
      • 6.4.10.2. Market Size and Forecast, By Application
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Type
    • 6.5.3. Market Size and Forecast, By Application
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Amebocyte Lysate Market
      • 6.5.5.1. Market Size and Forecast, By Type
      • 6.5.5.2. Market Size and Forecast, By Application
    • 6.5.6. Saudi Arabia Amebocyte Lysate Market
      • 6.5.6.1. Market Size and Forecast, By Type
      • 6.5.6.2. Market Size and Forecast, By Application
    • 6.5.7. South Africa Amebocyte Lysate Market
      • 6.5.7.1. Market Size and Forecast, By Type
      • 6.5.7.2. Market Size and Forecast, By Application
    • 6.5.8. Rest of LAMEA Amebocyte Lysate Market
      • 6.5.8.1. Market Size and Forecast, By Type
      • 6.5.8.2. Market Size and Forecast, By Application

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. Lonza Group AG
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. Charles River Laboratories
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Associates of Cape Cod Inc
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. Xiamen Bioendo Technology
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Zhanjiang A&C Biological
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. Genscript Technology Corporation
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Nelson Laboratories, LLC
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Thermo Fisher Scientific, Inc.
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. Merck And Co., Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. Microcoat Biotechnologie GmbH
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Developments